Cytokinetics Denies Ongoing $10B Novartis Buyout Amid Aficamten Breakthrough and IPO Speculation

The rumor that biopharmaceutical company Cytokinetics will be acquired by Swiss pharmaceutical giant Novartis has been circulating for several months, during which time Cytokinetics' stock price has fluctuated significantly due to the news. Recently, Cytokinetics' CEO Robert Blum denied the rumors, stating that they currently have no ongoing merger and acquisition transactions.

The origin of this potential deal can be traced back to Cytokinetics' research breakthrough in cardiac drugs.

In late December 2023, Cytokinetics, Inc., a pharmaceutical company headquartered in California, U.S., announced a breakthrough in the third phase of research for its innovative therapy Aficamten, which has shown significant efficacy in treating hypertrophic cardiomyopathy (HCM). HCM is the most common hereditary cardiovascular disease. According to the company's data, there are currently about 280,000 HCM patients in the U.S. alone, with two-thirds suffering from obstructive HCM and the remaining from non-obstructive HCM.

This breakthrough is not only a clinical success but also heralds a surge in Cytokinetics' future sales. Analysts at Truist predict that by 2032, annual sales of Cytokinetics' drugs will reach $3.6 billion; based on the late-stage trial data of Aficamten, the drug could become the best in its class, making Cytokinetics an attractive acquisition target. In fact, shortly after Cytokinetics announced the clinical data for Aficamten, the company's stock price soared, rising from $45 per share to $83 in a single day, an increase of up to 82%.

In early January this year, The Wall Street Journal was the first to report that Novartis was about to acquire Cytokinetics; Reuters followed up, stating that this acquisition deal would exceed $10 billion, with Novartis leading the bidding against competitors including AstraZeneca and Johnson & Johnson. As news of the acquisition spread, Cytokinetics' stock price further rose to a high of $110 per share, with a market value approaching $10 billion.

However, in mid-January, The Wall Street Journal and Reuters reported that the negotiations between the two parties had collapsed, and Novartis had terminated its acquisition of Cytokinetics. Although neither company commented on this rumored M&A deal, at that time, Novartis CEO Vasant Narasimhan publicly stated that Novartis’ overall M&A strategy focuses on smaller acquisitions, mostly assets valued below $5 billion.

The implication is that they won't buy if it's too expensive. Cytokinetics, whose market value has skyrocketed to 10 billion US dollars in a short period of time, may no longer be their desired target.

Until recently, Blum clarified during Cytokinetics' fourth-quarter earnings call that there were no ongoing merger and acquisition (M&A) deals. This rumored $10 billion healthcare M&A deal has been definitively put to rest by Blum. However, he assured shareholders that the company would consider all offers, hinting at the possibility of other deals.

"Our top priority is to focus on business development," Blum said. Clearly, obtaining sales approval for Aficamten and marketing it globally is the company's key focus. Meanwhile, Blum added that they are negotiating a deal regarding Aficamten with Japan, and discussions with all parties are proceeding smoothly.

Looking back at the news in mid-January that the Novartis and Cytokinetics acquisition deal fell through, Cytokinetics' stock price plummeted. Based on the latest stock price, the company's shares are currently around $66 each, having dropped by nearly half compared to the potential valuation of the acquisition deal in early January. This demonstrates the significant impact that acquisition rumors can have on a company’s market value.

In fact, it is not uncommon for pharmaceutical giants to rush to acquire biotech companies. Last year, AbbVie purchased two companies within a week, acquiring ImmunoGen for $10.1 billion and Cerevel Therapeutics for $8.7 billion.

AbbVie, the pharmaceutical giant based in Chicago, is known for selling Botox and Humira, a drug for immune diseases. However, its flagship product Humira began facing lower-priced competition last year, while sales of its cancer drug Imbruvica declined. Therefore, AbbVie has consistently expressed interest in acquisitions to strengthen its growth prospects.

AbbVie's acquisition of ImmunoGen can be seen as the company's move from liquid tumors into the solid tumor field. The cancer drugs developed by ImmunoGen are known as ADCs (antibody-drug conjugates), and ADCs have become the most competitive area in this field. Just last year, Pfizer reached a $43 billion deal with ADC pioneer Seagen, while Merck struck a $22 billion deal with Daiichi Sankyo.

Last August, during AbbVie's acquisition of Cerevel, Cerevel was conducting two mid-stage trials on a schizophrenia drug, the success of which was not guaranteed. However, AbbVie had strong confidence in the early data of emraclidine, a drug developed by Cerevel, believing it could offer patients effective benefits while avoiding severe side effects.

AbbVie Spent $8.7 Billion on Cerevel in Its Early Development Stage, Potentially Saving Billions Compared to Entering at Mid or Late Stages, While Also Avoiding Future Bidding Wars with Companies Like Eli Lilly and Pfizer. However, the Uncertainty Has Significantly Increased.

Notably, in December last year, pharmaceutical company Bristol Myers also reached an acquisition agreement with neuroscience drug development company Karuna Therapeutics, with the former set to acquire the latter for $14 billion.

Karuna's flagship product is KarXT, which is currently under FDA review for its efficacy in treating schizophrenia. Additionally, the drug is being further developed for use in Alzheimer's disease and bipolar disorder-related conditions. According to analyst predictions, if the drug is approved for various uses, its annual sales could exceed $6 billion.

Therefore, when Bristol Myers faced the situation where its old products started to lose patent protection, acquiring Karuna could serve as one of its springboards to capture the neuroscience treatment market.

After analyzing several major M&A deals in the pharmaceutical industry in recent years, it is not difficult to find that pharmaceutical giants usually face issues such as the expiration of drug patents under their own companies, declining annual sales, or falling stock prices when seeking M&A transactions.

In terms of transaction size, they tend to acquire companies valued between $7 billion and $12 billion, for two reasons: first, the acquired company must be of a certain scale to alter the group's landscape; second, the price cannot be so high as to attract antitrust investigations.

For example, Pfizer's $11.6 billion acquisition of Biohaven, Merck's $10.8 billion acquisition of Prometheus Biosciences, and Roche's $7.1 billion acquisition of Telavant Holdings. Although there are exceptions, many pharmaceutical M&A deals fall within this range.

Moreover, the timing of mergers and acquisitions is also crucial. Companies being acquired often have recently released strong clinical data or have just received approval for their first drug. The acquisition of Cerevel by AbbVie after the release of early research data, and the deal between Bristol Myers and Karuna during the drug approval stage, both fall into this category.

In this case, the rumor of Novartis acquiring Cytokinetics fits well with the conventional logic of pharmaceutical giants acquiring biopharmaceutical companies. As one of the largest pharmaceutical companies globally, several of Novartis's older products have recently lost patent protection, including its highly successful heart drug Entresto. Therefore, it is indeed seeking acquisition opportunities.

Cytokinetics, Inc. released the latest clinical data for its myocardial therapy, making it a highly attractive acquisition target. However, it is unclear whether the deal fell through due to excessive volatility in Cytokinetics' stock price or because Novartis preferred targets under $5 billion. In any case, there is now little certainty as to whether concrete negotiations ever took place.

M&A transactions themselves are full of various uncertainties. The buyer always feels they overpaid, while the seller feels they underpriced their assets. Although this rumored $10 billion M&A deal was not reached, the CEO of Cytokinetics has clearly stated that they are still seeking buyers. Novartis, facing the challenge of declining sales, will presumably continue to look for acquisition targets.

Perhaps this is the charm of mergers and acquisitions (M&A). The larger the amount, the more potential interest parties are involved, and the more uncertain factors come into play — from the acquirer to the target, from executives to employees, from the industry to the media, everything is a variable. Opinions also vary. Wei Jian Dan of PAG believes that the key to a successful M&A deal is to satisfy all parties. Jia Zhu of Bain Capital thinks the core opportunity in M&A lies in "shareholder absence," and the best approach is to align everyone's interests on the same chariot. On the side of publicly listed companies, there may be yet other answers. It’s an art of balance.